By Michael Dabaie

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. said imbruvica long-term data from two pivotal phase 3 studies demonstrated sustained efficacy and safety in patients with chronic lymphocytic leukaemia.

With up to six years of follow-up, results from the Resonate study showed patients with previously treated CLL receiving ibrutinib monotherapy sustained progression-free survival and overall survival benefits versus ofatumumab, Janssen said.

Five-year follow-up data from the Resonate-2 study showed sustained progression-free survival benefit in patients with previously untreated CLL receiving ibrutinib monotherapy versus chlorambucil, with an estimated overall survival rate of 83 percent reported in patients treated with ibrutinib, Janssen said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

June 03, 2019 11:16 ET (15:16 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson